Business Context and Reporting Period
This Form 8-K was filed by Zura Bio Limited (ZURA) on March 29, 2023. The filing reports a change in the company's independent registered public accounting firm following a business combination that closed on March 20, 2023. The company is an emerging growth company incorporated in the Cayman Islands.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the transition of the external auditor.
Material Changes
- Accountant Change: Zura Bio engaged WithumSmith+Brown, PC ("Withum") as its new independent registered public accounting firm to audit the fiscal year ending December 31, 2023.
- Termination of Prior Auditor: Marcum LLP ("Marcum") was terminated as the independent registered public accounting firm effective March 20, 2023, coinciding with the closing of the business combination.
- Audit Opinion Status: Marcum's report dated March 28, 2023, covering the period from inception through December 31, 2022, did not contain an adverse opinion, disclaimer, or qualification regarding uncertainties, audit scope, or accounting principles.
Outlook, Risks, and Contingencies
Disagreements and Reportable Events: The company reported no disagreements with Marcum regarding accounting principles, practices, or audit scope. However, the filing discloses a specific "reportable event": a material weakness in internal controls identified by management. This weakness relates to the lack of ability to account for complex financial instruments and the improper accounting and reporting of certain proceeds from the company's initial public offering in historical financial statements.
Consultations: The company confirmed it did not consult with the new auditor, Withum, on any matters that were the subject of a disagreement or reportable event prior to their engagement.
Investor Verification Checklist
- Verify the details of the material weakness in internal controls regarding complex financial instruments and IPO proceeds.
- Review the attached letter from Marcum LLP (Exhibit 16.1) to confirm their agreement with the company's disclosures.
- Monitor future filings for the remediation plan regarding the identified internal control weaknesses.
- Confirm the impact of the business combination on the company's capital structure and financial reporting standards.